Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × trametinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 29 Neoplasms 13 Multiple Myeloma 7 Thyroid Carcinoma, Anaplastic 6 Carcinoma, Non-Small-Cell Lung 6 Brain Neoplasms 6 Thyroid Neoplasms 5 Hematologic Neoplasms 5 Lymphoma 4 Glioma 4 Colorectal Neoplasms 4 Neurofibromatosis 1 3 Biliary Tract Neoplasms 3 Astrocytoma 3 Uveal Melanoma 2 Skin Neoplasms 2 Pancreatic Neoplasms 2 Neurofibroma, Plexiform 2 Neoplasm Metastasis 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Gastrointestinal Stromal Tumors 2 Cholangiocarcinoma 2 Bile Duct Neoplasms 2 Ameloblastoma 2 Triple Negative Breast Neoplasms 1 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Solid Tumor 1

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡